A009420 Stock Overview
A pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hanall Biopharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩31,950.00 |
52 Week High | ₩52,000.00 |
52 Week Low | ₩28,500.00 |
Beta | 0.79 |
1 Month Change | -14.00% |
3 Month Change | -15.92% |
1 Year Change | -15.03% |
3 Year Change | 54.35% |
5 Year Change | -8.84% |
Change since IPO | 3,095.00% |
Recent News & Updates
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%
Dec 09Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up
Oct 14Recent updates
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%
Dec 09Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up
Oct 14Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)
Jun 26Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely
May 22There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings
Mar 13Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years
Feb 12What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?
Jan 25Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 04Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?
Dec 14Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching
Nov 21Shareholder Returns
A009420 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -8.7% | 1.5% | -1.6% |
1Y | -15.0% | 3.2% | -9.1% |
Return vs Industry: A009420 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A009420 underperformed the KR Market which returned -9.1% over the past year.
Price Volatility
A009420 volatility | |
---|---|
A009420 Average Weekly Movement | 9.3% |
Pharmaceuticals Industry Average Movement | 5.8% |
Market Average Movement | 6.6% |
10% most volatile stocks in KR Market | 12.6% |
10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A009420's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A009420's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1973 | 309 | Seungwon Jeong | www.hanall.co.kr |
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology.
Hanall Biopharma Co., Ltd. Fundamentals Summary
A009420 fundamental statistics | |
---|---|
Market cap | ₩1.66t |
Earnings (TTM) | -₩6.29b |
Revenue (TTM) | ₩134.24b |
12.1x
P/S Ratio-257.7x
P/E RatioIs A009420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A009420 income statement (TTM) | |
---|---|
Revenue | ₩134.24b |
Cost of Revenue | ₩65.36b |
Gross Profit | ₩68.88b |
Other Expenses | ₩75.17b |
Earnings | -₩6.29b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -124.00 |
Gross Margin | 51.31% |
Net Profit Margin | -4.68% |
Debt/Equity Ratio | 0% |
How did A009420 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 16:40 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hanall Biopharma Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Seung Taek Oh | Cape Investment & Securities Co., Ltd. |
Ka-hye Hong | Daishin Securities Co. Ltd. |
Jonghyun Park | DAOL Investment & Securities Co., Ltd. |